NEW YORK (GenomeWeb News) — BioMérieux will exclusively distribute AdvanDx’s diagnostic tests in the US, the French company said Tuesday. 
The tests, which use in situ hybridization technology, may be used to identify Staphylococcus aureus, Candida albicans, Enterococcus faecalis and other species of bacteria in fewer than five hours, the companies said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.